CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...3839404142434445464748...39313932»
  • ||||||||||  Campath (alemtuzumab) / Sanofi
    Review, Journal:  Acute Coronary Syndrome as an Unusual Initial Presentation of T-Prolymphocytic Leukemia: A Case Report and Review of the Literature. (Pubmed Central) -  Sep 4, 2024   
    Despite known potential cardiotoxicity, the patient was treated with the anti-CD52 antibody alemtuzumab with a gradual dose increase from 3?mg to 30?mg per day...The reported case shows that T-PLL can also become initially symptomatic through an acute coronary syndrome on the basis of complex coronary heart disease. Targeted antileukaemic therapy with the monoclonal antibody alemzutumab can lead to effective systemic cytoreduction without cardiac dysfunction even in patients with severe cardiac disease, although cases of cardiotoxicity have been reported.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), PNT2002 / Lantheus, Eli Lilly
    Trial initiation date, Metastases:  PSMA Therapy and Immunotherapy in Kidney Cancer (clinicaltrials.gov) -  Sep 4, 2024   
    P1/2,  N=37, Not yet recruiting, 
    These results suggest that daratumumab may be an effective treatment option for iTTP patients with intolerance or refractoriness to rituximab. Initiation date: Jul 2024 --> Nov 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
    Journal:  PD-1 Targeted Antibody Discovery Using AI Protein Diffusion. (Pubmed Central) -  Sep 4, 2024   
    Initiation date: Jul 2024 --> Nov 2024 While there are already multiple FDA-approved anti-PD-1 antibodies, including nivolumab (Opdivo
  • ||||||||||  Jaypirca (pirtobrutinib) / Eli Lilly, Tecartus (brexucabtagene autoleucel) / Gilead
    Enrollment open:  Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL (clinicaltrials.gov) -  Sep 4, 2024   
    P2,  N=60, Recruiting, 
    While there are already multiple FDA-approved anti-PD-1 antibodies, including nivolumab (Opdivo Not yet recruiting --> Recruiting
  • ||||||||||  certepetide (LSTA1) / Lisata Therap
    Trial completion, Phase classification, Trial completion date, Trial primary completion date, Metastases:  CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) -  Sep 4, 2024   
    P1/2,  N=50, Completed, 
    No abstract available Recruiting --> Completed | Phase classification: P1b/2 --> P1/2 | Trial completion date: May 2023 --> Jun 2024 | Trial primary completion date: May 2023 --> Jun 2024
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer, Vizimpro (dacomitinib) / Pfizer
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  DELINOR: A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. (clinicaltrials.gov) -  Sep 4, 2024   
    P=N/A,  N=1, Completed, 
    Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Mar 2025 Recruiting --> Completed | N=20605 --> 1 | Trial completion date: Feb 2025 --> Jan 2024 | Trial primary completion date: Feb 2025 --> Jan 2024
  • ||||||||||  iscalimab (CFZ533) / Novartis
    Trial completion:  TWINSS Extn: Study of Safety and Tolerability of CFZ533 in Patients With Sj (clinicaltrials.gov) -  Sep 4, 2024   
    P2,  N=206, Completed, 
    Recruiting --> Completed | N=20605 --> 1 | Trial completion date: Feb 2025 --> Jan 2024 | Trial primary completion date: Feb 2025 --> Jan 2024 Active, not recruiting --> Completed
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, magrolimab (ONO-7913) / Ono Pharma
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  Phase II Trial of Magrolimab and Cetuximab with Pembrolizumab or Docetaxel for Recurrent/metastatic Head Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Sep 4, 2024   
    P2,  N=4, Terminated, 
    Trial completion date: Jul 2026 --> Jun 2030 | Trial primary completion date: Jul 2024 --> Jun 2030 N=57 --> 4 | Trial completion date: Nov 2029 --> Aug 2024 | Suspended --> Terminated | Trial primary completion date: Nov 2027 --> Aug 2024; Slow Accrual
  • ||||||||||  Epidaza (chidamide) / Chipscreen, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
    New P2 trial, Combination therapy, Metastases:  ACPC: Adebrelimab and Chidamide for Pancreatic Cancer (clinicaltrials.gov) -  Sep 4, 2024   
    P2,  N=77, Not yet recruiting, 
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Trial initiation date, Minimal residual disease, Circulating tumor DNA:  CONTINUE: ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC (clinicaltrials.gov) -  Sep 4, 2024   
    P2,  N=80, Not yet recruiting, 
    Higher pronase concentrations can be used as an auxiliary method to detect moderate-to-strong DSA reactions in RTX-treated patients. Initiation date: Jul 2024 --> Dec 2024
  • ||||||||||  LOXO-783 / Eli Lilly
    Enrollment closed, Enrollment change, Combination therapy, Monotherapy, Metastases:  PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov) -  Sep 4, 2024   
    P1,  N=193, Active, not recruiting, 
    Trial completion date: Mar 2024 --> Dec 2026 | Trial primary completion date: Mar 2021 --> Dec 2025 Recruiting --> Active, not recruiting | N=400 --> 193
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Real-world evidence, Patient reported outcomes, Real-world:  EAFToS: Characterizing the Use of Ofatumumab in a Real World Setting (clinicaltrials.gov) -  Sep 4, 2024   
    P=N/A,  N=103, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Jan 2024 Recruiting --> Active, not recruiting | N=1500 --> 103 | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
  • ||||||||||  GEN1042 / Genmab, BioNTech
    Trial completion date, Combination therapy, Monotherapy:  A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors (clinicaltrials.gov) -  Sep 4, 2024   
    P1,  N=30, Recruiting, 
    Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jul 2026 --> Oct 2026 Trial completion date: Oct 2027 --> Feb 2027
  • ||||||||||  Nulojix (belatacept) / BMS
    Trial completion date, Trial primary completion date:  Novel Desensitization Kidney Transplantation (clinicaltrials.gov) -  Sep 4, 2024   
    P1/2,  N=5, Recruiting, 
    Trial completion date: Oct 2027 --> Feb 2027 Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Sep 2024 --> Sep 2026
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  B-cell depletion works in IgG4-related disease. What else? (Pubmed Central) -  Sep 3, 2024   
    Imaging of the actual therapeutic administration of 124I-omburtamab allows for direct estimation of the therapeutic lesion and normal-tissue-absorbed doses. No abstract available
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Riesgo de c (Pubmed Central) -  Sep 3, 2024   
    Sphingosine-1-phosphate receptor modulators, such as fingolimod and siponimod are associated with a higher risk of basal cell carcinoma (BCC), but not squamous cell carcinoma, or melanoma...Alemtuzumab and cladribine show isolated associations with skin cancer...Given the evidence currently available, it is of paramount importance to advocate for necessary dermatological assessments that should be individualized to the risk profile of each patient. Nonetheless, additional prospective studies are still needed to establish efficient dermatological follow-up protocols.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Risk of skin cancer associated with disease-modifying therapies in multiple sclerosis: a modern comprehensive evidence review. (Pubmed Central) -  Sep 3, 2024   
    Sphingosine-1-phosphate receptor modulators, such as fingolimod and siponimod are associated with a higher risk of basal cell carcinoma (BCC), but not squamous cell carcinoma, or melanoma...Alemtuzumab and cladribine show isolated associations with skin cancer...Given the evidence currently available, it is of paramount importance to advocate for necessary dermatological assessments that should be individualized to the risk profile of each patient. Nonetheless, additional prospective studies are still needed to establish efficient dermatological follow-up protocols.
  • ||||||||||  tomivosertib (eFT508) / eFFECTOR Therap
    Journal:  Tomivosertib reduces ectopic activity in dorsal root ganglion neurons from patients with radiculopathy. (Pubmed Central) -  Sep 3, 2024   
    Parallel to the effects on electrophysiology, eFT508 treatment led to a profound loss of eIF4E serine 209 phosphorylation in primary sensory neurons, a specific substrate of MNK, within 2 min of drug treatment. Our results create a compelling case for the future testing of MNK inhibitors in clinical trials for neuropathic pain.
  • ||||||||||  Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
    P2 data, Journal:  Ibrutinib plus rituximab and mini-CHOP in very elderly patients with newly diagnosed DLBCL: A phase II ALLG study. (Pubmed Central) -  Sep 3, 2024   
    In both health-related quality of life measures, there was an improvement in functional and symptom scales, median health state classification score and median visual analogue scale in responders over time. In conclusion, this study showed that the addition of ibrutinib to R-mini-CHOP was both deliverable and efficacious in elderly DLBCL patients.